Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
NewLink Genetics Corp (NASDAQ:NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE:MRK) and Incyte Corporation (NASDAQ:INCY) said their clinical trial of the similar drug epacadostat failed to meet expectations.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Cantor Fitzgerald's Mara Goldstein downgraded NewLink Genetics' stock rating from Overweight to Neutral with a price target slashed from $26 to $7.
The Thesis
Incyte's failed clinical study of a therapy similar to NewLink's indoximod resulted in NewLink's stock falling more than 40 percent Friday, despite the fact that the two therapies have different profiles and differentiated mechanisms, Goldstein said in the downgrade note. (See the analyst's track record here.)
NewLink's decision to revisit its own clinical program is reason enough to downgrade the stock, as it "casts a shadow" on its programs, including indoximod, Goldstein said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
If NewLink's management doesn't offer investors greater visibility on the clinical steps for its program, then the stock is unlikely to regain much of the value it lost Friday, the analyst said. Cantor's revised $7 price target is based on the following, Goldstein said:
- A longer development time frame for indoximod from 2025 to 2028.
- A discount rate raised from 40 percent to 60 percent.
- A lower probability of ultimate success.
- The platform value for other programs that are ongoing.
Price Action
Shares of NewLink Genetics were trading lower by more than 4 percent at the time of publication Monday.
Leerink: Armo Biosciences' 'Promising' Data Justifies A Bullish Stance
Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.